Effects of rhBAFF and/or BR3-Fc on apoptosis of CD19⁺, CD8⁺ cells, platelets, and secretion of IFN-γ in active ITP patients and controls. (A) RhBAFF significantly decreased the annexin V percentage of CD19⁺ cells in ITP patients (8.5% vs 13.1%, P < .01) but not in controls. BR3-Fc corrected the effect of rhBAFF on apoptosis of CD19⁺ cells in ITP patients (11.4% vs 8.5%, P < .05). (B) RhBAFF significantly decreased the annexin V percentage of CD8⁺ cells in ITP patients and controls. BR3-Fc corrected the effect of rhBAFF on apoptosis of CD8⁺ cells only in ITP patients. (C) RhBAFF (20 ng/mL) significantly promoted the annexin V percentage of platelets only in ITP patients (7.3% vs 3.3%, P < .05); BR3-Fc corrected the effect of rhBAFF on apoptosis of platelets (4.7% vs 7.3%, P < .05). Compared with controls, there was significantly increased annexin V percentage of platelets in group I in ITP patients (3.3% vs 1.3%, P < .05). (D) RhBAFF (20 ng/mL) significantly promoted the secretion of IFN-γ in ITP patients (95.1 pg/mL vs 74.0 pg/mL, P < .05) but not in controls; BR3-Fc corrected the effect of rhBAFF in patients. Compared with controls, there was significantly increased expression of IFN-γ in ITP patients in each group (P < .01). Bars represent SD; *P < .05; **P < .01.